Dosing modifications for adverse reactions1
- Monitor patients for rash throughout the treatment course
- Rash (drug eruption) may be visually indistinguishable from disease progression
- Consider skin biopsy to help make a differential diagnosis
Common signs of infusion reactions
chills | nausea | fever | tachycardia | rigors | headache | vomiting
aNCI-CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events.
Use in special populations
No clinically significant changes in the pharmacokinetics of POTELIGEO were observed based on age, renal impairment, or mild/moderate hepatic impairment. As a result, no corresponding dose modifications are required.
- In MAVORIC, 51% of patients treated with POTELIGEO were 65 years of age or older (range: 25 to 101)
- No overall differences in effectiveness were observed between patients 65 or older and younger patients
- Patients 65 or older had a greater number of grade 3 or higher adverse reactions than patients under 65, but the difference was not statistically significant
For more information on dosing, see the POTELIGEO Dosing and Administration Guide
- POTELIGEO [package insert]. Kyowa Kirin Inc., Bedminster, NJ USA.
- Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Published November 27, 2017. US Department of Health and Human Services. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed May 18, 2021.